Synonyms: compound 47 [PMID: 34699203] | GSK-329
Compound class:
Synthetic organic
Comment: GSK329 is a small molecule inhibitor of cardiac-specific kinase TNNI3K (TNNI3 interacting kinase) [1]. It was derived from the scaffold of the multi-kinase inhibitor sorafenib (IC50 100nM vs. TNNI3K). GSK329 is suitable as an in vivo tool to assess inhibition of TNNI3K as a novel therapeutic strategy for the treatment of cardiovascular diseases.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
GSK329 was designed to be selective for TNNI3K compared to VEGFR2, p38α, and BRaf [1]. It is 40-fold more selective for human TNNI3K compared to VEGFR2, 80-fold selective against p38α, and and >200-fold selective against B-Raf. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|